TXG10x Genomics, Inc.
Is the price fair?
Priced for +14% a year vs +3% a year delivered. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~14% a year FCF growth. The price demands more than its three-year revenue growth of 3% a year, priced for acceleration.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What TXG's price assumes
10x Genomics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 7.06× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 2.7%
Free cash flow yield · Health Information Services median 6.3%
- Growth the price implies
- +14%
Growth the price implies · The price pays for +14% free cash flow growth a year for a decade; revenue has grown +2.8% a year over the last three.
- Price / book
- 5.70
Price / book · today's price, fiscal year to Dec 31, 2025
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 5.70
- EV / EBIToperating margin −14%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 6.98
- Free cash flow, trailing twelve months
- $121M
- Market capitalisation
- $4.54B
- 3-year revenue growth
- +2.8%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Health Information Services
Ranks #16 of 20 by RyuScore